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ABSTRACT 
HYDROXYCHLOROQUINE PREVENTS ANTIPHOSPHOLIPID ANTIBODY-
INDUCED INHIBITION OF TROPHOBLAST MIGRATION 
Women with antiphospholipid syndrome (APS) are at high risk of recurrent pregnancy 
complications. Antiphospholipid antibodies (aPL) target the trophoblast by binding beta2-
glycoprotein I (β2GPI) and alter human first trimester trophoblast function by: triggering 
a pro-inflammatory cytokine response; modulating angiogenic factor secretion; and 
inhibiting cell migration. While patients with APS are often treated with 
hydroxychloroquine (HCQ), and it is safe to use during pregnancy, little is known about 
the effects of HCQ on aPL-associated adverse pregnancy outcomes. Therefore, the 
objective of this study was to test the hypothesis that HCQ prevents the effects of aPL on 
human first trimester trophoblast function. A human first trimester trophoblast cell line 
was treated with or without anti-human β2GPI monoclonal antibodies in the presence or 
absence of HCQ. Using ELISA, culture supernatants were analyzed for: pro-
inflammatory cytokines IL-8 and IL-1β; pro-angiogenic factors VEGF and PlGF; anti-
angiogenic factors sFlt-1 and soluble Endoglin; pro-migratory cytokine IL-6; and tissue 
inhibitors of metalloproteinase 1 and 2 (TIMP1 and TIMP2). Cell migration was 
measured using a colormetric two-chamber assay. The aPL-induced upregulation of 
trophoblast IL-8, IL-1β, PlGF, and sEndoglin secretion was not significantly altered by 
the presence of HCQ. The presence of HCQ partially, yet significantly, reversed the aPL-
induced inhibition of trophoblast cell migration and secretion of pro-migratory cytokine 
IL-6. aPL-induced upregulation of trophoblast TIMP secretion appears to inhibit cell 
migration. HCQ was unable to completely prevent aPL-induced TIMP secretion, and this 
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may explain why migration was only partially restored. HCQ reversed the aPL-induced 
inhibition of IL-6 secretion and partially limited the ability of aPL to reduce trophoblast 
cell migration. Our data indicate the possibility that some form of combination therapy 
that includes HCQ may be beneficial to pregnant APS patients and warrants further 
investigation. 
 
Published in American Journal of Reproductive Immunology:  
Albert, C.R., Schlesinger, W.J., Viall, C.A., Mulla, M.J., Brosens, J.J., Chamley, L.W., 
and Abrahams, V.M. 2014. Effect of hydroxychloroquine on antiphospholipid antibody-
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INTRODUCTION 
 
Classification of Antiphospholipid Syndrome  
Antiphospholipid syndrome (APS), an autoimmune systemic disease characterized by 
circulating antiphospholipid antibodies (aPL), places women at risk of adverse pregnancy 
outcomes, such as recurrent pregnancy loss and late gestational complications including 
preeclampsia and associated premature delivery, HELLP syndrome (hemolytic anemia, 
elevated liver enzymes, and low platelet counts), and intrauterine growth restriction (1). 
Complications such as preeclampsia are also known to increase health risks for the 
mother later in life, including hypertension and cardiovascular disease (2). While health 
consequences for the neonate are known to be related to low birth weight and 
prematurity, several studies have suggested potential negative long-term cognitive and 
psychological outcomes, including autism spectrum and other neurodevelopmental 
disorders (3, 4).  
 
Methods of treatment for APS during pregnancy typically involve low molecular weight 
heparin (LMWH), either alone or in combination with aspirin (5, 6). In some studies, this 
treatment has been shown to significantly increase the live birth rate in APS patients who 
have experienced multiple miscarriages. However, the incidence of severe late obstetric 
complications, including preeclampsia, intrauterine growth restriction and prematurity, 
remains high (5, 6). In addition, clinical and experimental studies have produced 
contradictory results regarding the effectiveness of heparin in preventing adverse 
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pregnancy outcomes in APS (7-10). Therefore, the development of improved strategies 
for the prevention of pregnancy complications in APS is a pressing concern.    
 
APS was recognized as a unique form of autoantibody-induced thrombophilia in the early 
1980s (11). The true frequency of APS is unknown, but it is estimated that the incidence 
is around 5 new cases per 100,000 persons per year, and the prevalence is around 40-50 
cases per 100,000 persons (12). The male-to-female ratio is about 1:3.5, and the mean age 
of onset is 35 years (13). APS is specifically characterized by recurrent thrombosis and 
pregnancy complications. Other manifestations include cardiac valvular disease renal 
thrombotic microangiopathy, thrombocytopenia, hemolytic anemia, and cognitive 
impairment (11). In fact, APS is the most common cause of acquired thrombophilia in the 
general population. Up to twenty percent of patients who have had a stroke at less than 
fifty years of age have been found to have circulating aPL (11). APS may occur as a 
primary disease, or may occur as secondary to another autoimmune disease, including 
systemic lupus erythematosus (SLE), rheumatoid arthritis, Sjogren’s syndrome, and 
certain malignancies (14, 15). In fact, forty percent of patients diagnosed with SLE with 
have circulating aPL (11).  
 
Diagnosis of APS must involve at least one clinical criterion and one laboratory criterion. 
Clinical criteria involve either vascular thrombosis or obstetric morbidity. Vascular 
thrombosis must be confirmed by Doppler study, imaging, or histopathology. Obstetric 
morbidity must include at least one unexplained fetal demise beyond ten weeks of 
gestation (with a morphologically normal fetus), at least one premature birth due to 
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eclampsia/preeclampsia/placental insufficiency, or at least three unexplained consecutive 
and spontaneous miscarriages before ten weeks gestation (11, 15, 16).  Laboratory 
criteria include the presence of anticardiolipin antibodies, anti-beta2-glycoprotein I 
antibodies, or lupus anticoagulant (15).  
 
Pathogenesis of Systemic and Obstetric Antiphospholipid Syndrome 
The pathogenesis of APS involves acquired antibodies (aPL), which are IgG, IgM, or IgA 
subtypes that react against negatively charged phospholipids. Such antibodies include, as 
discussed above, anticardiolipin antibodies, anti-beta2-glycoprotein I antibodies, and 
lupus anticoagulant (14). The main autoantigen for APS is beta2-glycoprotein I (β2GPI), a 
protein localized to the plasma membrane that mediates aPL binding to target cells such 
as platelets, monocytes, endothelial cells, and trophoblasts (14). These antibodies 
increase thrombus formation in both the arterial and venous circulation. Prothrombotic 
effects of aPL involve inhibition of the fibrinolytic system and activation of the 
coagulation cascade, activation of the complement system, and inhibition of annexin A5, 
a potent anticoagulant protein on endothelial cell surfaces (14).  
 
Despite the association of APS with thrombosis and the success of anticoagulants such as 
heparin in preventing pregnancy loss, recent studies have shown that intravascular or 
intravillous blood clots are not typically found in placental samples from APS patients 
(17). Rather, clinical and experimental studies suggest that the primary causes for adverse 
pregnancy events are inflammatory processes, including cytokine production, 
complement deposition, and immune cell activation (18-22). Furthermore, studies 
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indicate that there is placental dysfunction and insufficient placentation in APS-
complicated pregnancies (17, 23, 24). Placental dysfunction in APS appears to be related 
to reduced migration of trophoblast cells and trophoblast invasion, as well as limited 
uterine spiral artery transformation (17, 23, 24).  
 
Antiphospholipid antibodies are able to specifically target the placenta by binding β2GPI 
(25-27). β2GPI is a phospholipid-binding protein that binds with high affinity to the 
negatively charged phospholipids on the inner cell membrane. Typically, cells only bind 
β2GPI under pathologic and apoptotic conditions, as this is the only time that the 
negatively charged inner phospholipids will be exposed to the outer membrane. However, 
the trophoblast is unique because it constitutively expresses β2GPI on its cell surface 
under normal circumstances, due to the high levels of proliferation and differentiation 
(25, 28). In addition, the trophoblast synthesizes β2GPI itself, increasing the levels of cell 
surface expressed and circulating β2GPI in the local environment. β2GPI has been shown 
to be expressed on the surface of extravillous trophoblast cells that invade the decidua of 
the uterus, as well as on the syncytiotrophoblast cells (28). The placenta is, therefore, a 
major target for circulating aPL, which recognize β2GPI. 
 
Physiology of Placentation 
Normal placentation occurs at six or seven days after conception, with the adhesion of the 
blastocyst to the uterine wall and the trophoectoderm giving rise to the placental 
trophoblast cells. The trophoblast layer of the placenta consists of an inner 
cytotrophoblast, which contains the stem cells that proliferate and differentiate. The 
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second layer is the syncytiotrophoblast, which is formed from the differentiation and 
fusion of cytotrophoblast cells. The cytotrophoblast cells invade the decidua, the 
proliferative layer of the uterus present during pregnancy. Cytotrophoblasts eventually 
differentiate into extravillous trophoblast cells, which migrate from the trophoblast layer 
to invade the entire endometrium and the inner third of the myometrium (28, 29). These 
cells remodel the maternal spiral arteries, resulting in increased blood flow to the 
placenta.  
 
The innate invasiveness of cytotrophoblasts is driven by both autocrine and paracrine 
signals. Signals like interleukin-6 (IL-6) produced by the trophoblast can drive migration 
through activation of the STAT3 pathway (24, 30, 31). Similarly, factors produced by the 
decidua, such as leukemia inhibitory factor (LIF) and IL-11, can also promote trophoblast 
invasiveness (31, 32). Trophoblast invasiveness is also related to the secretion and 
balance of proteinases such as matrix metalloproteinases (MMPs) and tissue inhibitors of 
metalloproteinases (TIMPs) (29). MMPs, a family of zinc-dependent endopeptidases, 
function by degrading and remodeling components of the extracellular matrix. Several 
human MMPs have been identified, including collagenases, gelatinases, and membrane-
associated MMPs (33). TIMPs belong to a family of endogenous extracellular proteins 
that function as MMP inhibitors by directly binding MMPs or by activating nuclear 
transcription factors that control the expression of MMPs (33). Several studies have 
indicated that the levels of MMP2, MMP9, TIMP1, and TIMP2 are particularly important 
for trophoblast invasion (34, 35). Abnormally low levels of MMP2 and MMP9 and 
abnormally high levels of TIMP1 and TIMP2 have been implicated in adverse pregnancy 
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outcomes such as preeclampsia and maternal hypertension (33, 34). The normal invasion 
of the decidua and remodeling of the maternal vasculature are impaired in disease states 
such as preeclampsia, preterm birth, and miscarriage (36). In these cases, there is 
inadequate remodeling of the maternal vasculature, shallow invasion of the decidua by 
trophoblast cells, and increased inflammation at the maternal-fetal interface (23, 28).  
 
Effects of Antiphospholipid Antibodies on the Trophoblast 
Many studies have investigated the potential mechanisms by which aPL affect 
trophoblast function by examining placental specimens from patients with APS or using 
murine models of APS in pregnancy (19, 21, 22). These studies have noted the existence 
of necrosis and acute and chronic inflammation in placental tissue from APS patients 
(22).  In addition, they have implicated aPL-induced upregulation of complement C5 
levels, neutrophil response, and tissue factor production as mediators of fetal injury in 
APS, leading to increased inflammation in the decidua and to subsequent miscarriages 
(19, 21). Many in vitro studies have examined the effects of aPL on term trophoblast 
cells. The presence of aPL has been shown to be associated with overall decreased 
viability of term trophoblast cells, with decreased trophoblast proliferation and increased 
trophoblast cell death (37). In addition, studies have noted that term trophoblast cells 
exposed to aPL demonstrate decreased syncytialization and decreased giant cell 
formation (38-40). Term trophoblast cells exposed to aPL have also been shown to 
produce reduced levels of syncytiotrophoblast hormones such as hCG (37, 41, 42). 
Several studies have shown the presence of aPL is associated with decreased term 
trophoblast cell invasion, although it should be noted that term trophoblast cells have 
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decreased invasive capacity than earlier gestational trophoblast cells (38, 43). Finally, 
term trophoblast cells exposed to aPL have been shown to have increased levels of 
prothrombotic thromboxane and decreased levels of antithrombotic annexin V (44, 45).   
 
Such studies are helpful in elucidating the effects of aPL in the late gestational and term 
trophoblast. However, aPL are always present in patients and are therefore present at the 
time of implantation and early in pregnancy. Moreover, obstetric APS includes placental 
insufficiency and preeclampsia, which are thought to be established early in pregnancy 
due to impaired early placental implantation and differentiation. Therefore, an 
investigation of the effects of aPL on first trimester trophoblast cells is critical. Indeed, 
studies from the laboratory have begun to examine the effects of aPL on human first 
trimester trophoblast function and some of the mechanisms involved (20, 24, 46). aPL 
trigger human first trimester trophoblast cells to produce elevated levels of pro-
inflammatory cytokines and chemokines, such as IL-8, IL-1β, through activation of the 
innate immune receptor, Toll-like receptor 4 (TLR4) (20). aPL have also been shown to 
alter first trimester trophoblast function by inhibiting trophoblast migration (24). This 
inhibition of migration has been linked to an aPL-induced downregulation of IL-6, a 
cytokine that normally promotes cell migration through the phosphorylation and 
activation of STAT3 (31). Indeed, aPL have been shown to decrease levels of both IL-6 
and phosphorylated STAT3 (24). In addition, aPL have been shown to modulate the 
trophoblast angiogenic factor profile by increasing pro-angiogenic vascular endothelial 
growth factor (VEGF) and placenta growth factor (PlGF), as well as increasing anti-
angiogenic soluble Endoglin (sEndoglin) secretion (46). Finally, aPL have been 
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implicated in the modulation of MMPs and TIMPs. Specifically, aPL have been shown to 
be associated with downregulation of MMP-2 and MMP-9 in primary cultures obtained 
from first trimester placental samples, in a first trimester trophoblast cell line, and in a 
human choriocarcinoma cell line (47, 48). An additional study has shown that aPL 
downregulate MMP-2 and MMP-9 in term trophoblast cells (43). 
 
The identification of therapeutic interventions that can prevent such trophoblast responses 
to aPL may translate clinically to improved pregnancy outcomes in APS patients. Indeed, 
this in vitro model has been used to assess the potential impact of heparin, aspirin, 
aspirin-triggered lipoxin, and pravastatin on trophoblast responses to aPL (9, 20, 24, 46, 
49, 50). These studies have reported that LMWH may have some benefits, specifically in 
terms of partially reversing the upregulation of pro-inflammatory cytokines IL-8 and IL-
1β (9). LMWH has also been shown to have some benefit in reversing the 
downregulation of MMP-2 (51). However, LMWH has also been shown to increase 
levels of anti-angiogenic factor soluble fms-like tyrosine kinase-1 (sFlt-1) (46).  This 
could potentially have an adverse effect on pregnancy, as increased levels of sFlt-1 have 
been associated with preeclampsia, and overexpression of sFlt-1 in mice leads to 
preeclampsia-like symptoms (52-54). Aspirin-triggered lipoxin has been shown to have 
some benefit in restoring IL-6 levels and cell migration (50). Due to these limited 
benefits, there is a need to evaluate the efficacy of alternative therapeutics, especially 
those that may help reverse the aPL-induced modulation of trophoblast angiogenic factor 
secretion and impaired trophoblast migration. 
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Mechanism of Action of Hydroxychloroquine 
Patients with SLE and APS are often treated with the anti-malarial drug 
hydroxychloroquine (HCQ), which has been shown to be beneficial in their management 
(55, 56). Quinines were first recognized as anti-malarial agents over hundreds of years 
ago, with their first use traditionally attributed to Incan descendants in Peru in 1630, who 
used a bark powder to treat a febrile illness (57). During World War II, the widespread 
use of quinines as malarial prophylaxis for soldiers led to the discovery that soldiers’ 
rashes and inflammatory arthritis improved as well, leading to the first trial showing 
antimalarials were effective in the treatment of SLE (57). In more recent times, such 
antimalarials have become established agents for treating rheumatic diseases such as 
SLE, Sjogren’s syndrome, chronic Q fever, and skin diseases (55).  
 
In addition to having anti-thrombotic effects, HCQ has anti-inflammatory and 
immunomodulatory properties, which recent studies have sought to characterize (55, 56, 
58, 59). Chloroquines are lipophilic, and thus cross cell membranes readily (56). As weak 
bases, chloroquines accumulate in lysosomes, increase the pH of the intracellular 
compartment, and impair the function of phagocytosis that normally requires lysosomal 
acidification for protease functioning. (60).  In addition, chloroquines have been shown to 
decrease the production of inflammatory cytokines, including IL-1, IL-2, IL-6, IL-17, IL-
22, interferon-alpha and gamma, and tumor necrosis factor-alpha (57, 61, 62). HCQ is 
also proposed to inhibit the effects of prostaglandins by inhibiting phospholipase A2 (57).  
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More recently, HCQ has been shown to affect TLR signaling (56). Specifically, 
antimalarials such as HCQ are thought to inhibit the activation of intracellular TLRs, 
such as TLR3, TLR7, TLR8 and TLR9 (59, 63). Such TLRs normally bind nucleic acids 
(bacterial and viral) into late endosomes and early lysosomes, but are also known to bind 
endogenous genetic material, which perhaps evolved as a response to damaged tissue (62, 
63). Such TLRs are implicated in the pathogenesis of autoimmune diseases such as APS 
and lupus, due to the presence of antibodies directed at nucleic material. Chloroquines, 
which target microsomes and disrupt the acidic pH as described above, are therefore 
postulated to block such TLR interaction with nucleic acids (59). However, an alternative 
pathway has also been proposed, in which chloroquines inhibit TLR activation by 
directly binding to nucleic acids and masking their TLR-binding epitope, rather than 
functioning by inhibiting endosomal proteolysis as previously thought (58). A further 
proposed mechanism suggests that HCQ may function by preventing the phosphorylation 
and activation of mitogen-activated protein kinases, thus preventing the downstream 
effects of lipopolysaccharide-induced inflammatory response via TLR4 (64). Studies 
from our group have demonstrated that aPL induce trophoblast inflammation via TLR4 
(20). Moreover, recent evidence suggests that trophoblast fusion and differentiation are 
inhibited by aPL via a TLR4-mediated pathway, and that HCQ is able to reverse this 
effect (40).  
 
Safety of Hydroxychloroquine 
HCQ is known to be a very safe medication when taken at therapeutic doses, but toxicity 
is recognized at doses above the safety margin (65). Toxic manifestations include 
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cardiovascular events such as hypotension, decreased myocardial function, cardiac 
arrhythmias, and cardiac arrest (57, 65). It is also known to have CNS toxicity, causing 
confusion, convulsions, and coma. At typical oral doses used for rheumatic disease, the 
main side effects of chloroquines are nausea, headache, and pruritus. Irreversible 
retinopathy and ototoxicity are possible at high daily doses, typically above 250 mg per 
day (66). Currently, the American Academy of Ophthalmology recommends a baseline 
screening ophthalmologic exam to all patients beginning hydroxychloroquine, followed 
by annual screening after five years of medication use (62). 
 
HCQ is known to cross the placenta, with fetal levels shown to be equivalent to maternal 
levels (67). However, HCQ is considered safe to use during pregnancy, with no evidence 
of fetal toxicity or congenital abnormalities (62, 67-70). Studies have specifically 
examined the association of HCQ exposure in utero with fetal ocular toxicity and found 
no evidence (71). However, little is known about the effects of HCQ on aPL-induced 
adverse pregnancy outcomes. Recent studies have reported that HCQ reduces the binding 
of aPL-β2GPI complexes to phospholipid bilayers and protects the anticoagulant protein 
annexin A5 from disruption by aPL in the term trophoblast, again by reduced antibody 
binding (72-74). Such studies suggest that HCQ might be able to prevent many of the 
effects of aPL on the trophoblast cell that are downstream effects of aPL binding to 
β2GPI.  
 
Since circulating aPL are present in women with APS at the time of implantation, the 
objective of this study was to investigate the impact that HCQ has on human first 
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trimester trophoblast cell responses to aPL. The ultimate goal of this study was to 
determine whether HCQ could be used as a therapy to prevent adverse pregnancy 
outcomes in women with APS. The specific hypotheses of this project were: 
1. HCQ can prevent the TLR4-mediated pro-inflammatory cytokine response triggered 
by aPL 
2. HCQ can prevent the aPL-induced modulation of pro- and anti-angiogenic factor 
secretion 
3. HCQ can prevent the aPL-induced inhibition of IL-6 production and cell migration 





Trophoblast Cell Line 
The human first trimester trophoblast cell line, SVneo transformed HTR8, was used in all 
experiments. The cell line (HTR8) was a gift from Dr. Charles Graham (Queen's 
University, Kingston, ON, Canada). This cell line was established from explant cultures 
of first trimester (7 weeks of gestation) chorionic villi. The cells were immortalized 
through transfection with cDNA encoding the simian virus-40 large T antigen (75). This 
cell line has been well characterized and shown to express various cell markers 
characteristic of extravillous invasive trophoblast cells (76). As extravillous trophoblast 
cells are responsible for invasion of the decidua and transformation of the spiral arteries, 
this cell line is an excellent in vitro model for studies of mechanisms regulating the 
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human first trimester trophoblast growth, migration, and invasion that is associated with 
normal placentation. 
 
HTR8 cells were grown in sterile 75 cm2 polystyrene cell culture flasks at 37°C/5% CO2. 
The culture media used was RPMI-1640 (Gibco; Grand Island, NY), supplemented with 
10% fetal bovine serum (Hyclone; South Logan, UT), 10 mM Hepes, 0.1 mM MEM non-
essential amino acids, 1 mM sodium pyruvate, and 100 nm penicillin/streptomycin 
(Gibco). The cells were grown until confluent, at which point they were split and plated 
for experiments or maintained in continued culture.  
 
The cells were split through the use of 3-5 mL of 0.05% Trypsin followed by activation 
with a brief incubation at 37°C until the cells had detached. An equal volume of culture 
media was added to inactivate the trypsin and the solution was transferred to a sterile 10 
mL polypropylene tube and centrifuged at room temperature at 3000 rpm for 10 minutes. 
The pellet was resuspended in growth media and the cells were counted and either plated 
for future experimentation or seeded into T75 for further propagation. 
 
Antiphospholipid Antibodies 
The aPL used in all experiments were the mouse IgG1 anti-human β2GPI mAbs, ID2 and 
IIC5. These antibodies were produced by Larry W. Chamley (Department of Obstetrics 
and Gynecology, University of Auckland, New Zealand), and have been previously 
characterized (77). ID2 and IIC5 bind β2GPI in the same manner as human aPL when 
immobilized on a suitable negatively charged surface, such as the phospholipids, 
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cardiolipin or phosphatidyl serine, or irradiated polystyrene (78). ID2 and IIC5 have been 
shown to alter trophoblast function similarly to patient-derived polyclonal aPL upon 
binding to first trimester trophoblast cells (20, 46).  
 
Cell Viability Assay 
Trophoblast cell viability was determined using the CellTiter 96 viability assay 
(Promega, Madison, WI), as previously described (79). Cells (1x104) were seeded into 
wells of a 96-well plate in growth media and incubated overnight. The media was then 
replaced with serum-free OptiMEM (Invitrogen; Carlsbad, CA), and cells were incubated 
for another 4 hours. Cells were then treated with HCQ (Sigma Aldrich) at concentrations 
of 0, 0.01, 0.1, 1, 10 and 100 µg/ml. HCQ was reconstituted in endotoxin-free water and 
subsequent dilutions made using OptiMEM prior to treatment. After 48 hours, the 
CellTiter 96 substrate (Promega) was added to all wells and incubated for 2 hours at 
37°C. Optical densities were read at 490 nm. All samples were assayed in triplicate, and 
cell viability was presented as a percentage of the untreated control (0µg/ml). 
 
Cytokine, Angiogenic Factor, and TIMP Secretion 
Trophoblast cells (1x105) were seeded into 35 mm tissue culture dishes in growth media 
and allowed to adhere overnight. After cells were 70% confluent, the growth media was 
replaced with serum-free OptiMEM (Invitrogen) and cells incubated for another 4 hours. 
Cells were then treated with or without aPL (ID2 or IIC5) at 20µg/ml in OptiMEM 
(Invitrogen) in the presence and absence of HCQ at 1µg/ml. After 72 hours, cell-free 
supernatants were collected by centrifugation at 400g for 10 minutes and stored at -80˚C 
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until analysis was performed. At the time of analysis, the supernatants were thawed on 
ice. The concentrations of interleukin 8 (IL-8), interleukin 1β (IL-1β), interleukin 6 (IL-
6), vascular endothelial growth factor (VEGF), placenta growth factor (PlGF), soluble 
fms-like tyrosine kinase-1 (sFlt-1), soluble Endoglin (sEndoglin), tissue inhibitor of 
metalloproteinase 1 (TIMP1) and tissue inhibitor of metalloproteinase 2 (TIMP2) were 
measured by ELISA (R & D Systems; Minneapolis, MN). 
 
Cell Migration 
To assess trophoblast migration, a two chamber colorimetric assay was used, as 
previously described (24). An 8µm pore size cell culture insert served as the top chamber 
(BD Biosciences, Franklin Lakes, NJ, USA), while the lower chambers were wells of a 
24-well tissue culture plate (BD Falcon, Franklin Lakes, NJ, USA). The lower chamber 
was filled with 800µL of OptiMEM while the top chamber was seeded with 1 x 105 cells 
HTR8 cells suspended in 200µL of treatments. Following a 48-hour incubation, the 8µm 
inserts were removed and trophoblast migration across the membrane was determined 
using the QCM 24-Well Colorimetric Cell Migration assay according to the 
manufacturer’s instructions (Chemicon International, Temecula, CA).  Briefly, migrated 
cells were stained, collected, and lysed. The resulting colored mixture was transferred to 
a 96-well plate and optical densities read in triplicate at 560 nm. A 100% migration 
control consisted of the starting number of cells (1 x 105). Observed optical density 
values were measured using a BioRad plate reader (Hercules, CA, USA), and were 
expressed as a percentage of the starting total number of cells. 
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Statistical Analysis 
All experiments were performed at least three times.  Data from individual experiments 
were pooled and expressed as mean ± standard error of the mean (SEM). Statistical 
significance was set at p<0.05 and was determined by one-way ANOVA using Prism 
software (GraphPad Software, Inc., La Jolla, CA). 
 
I produced the data for the all of the cell viability studies, cytokine and angiogenic factor 
studies, and migration studies, with the exception of the data for the TIMP1 and TIMP2 
studies, which were produced by Mr. Schlesinger. With the help of Dr. Abrahams, I 





HCQ decreases trophoblast viability at high doses 
The first objective of this study was to determine the concentration range of HCQ that 
has no trophoblast cytotoxicity. Figure 1 shows that the two highest HCQ doses tested, 
10µg/ml and 100µg/ml, significantly reduced trophoblast cell viability when compared to 
the untreated control (0µg/ml). At all others concentrations tested, there was no 
significant effect on cell viability (Figure 1). Therefore, for all subsequent experiments, 
the highest non-cytotoxic dose of 1µg/ml HCQ was used, which is consistent with 
previous reports studying the effects of HCQ on the trophoblast (72-74). 
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Figure 1: High levels of HCQ reduce trophoblast cell viability. The first trimester trophoblast cell line 
(HTR8) was incubated with no treatment (0µg/ml) or HCQ at 0.01, 0.1, 1, 10 or 100µg/ml for 72hrs. Chart 
shows cell viability as a percentage of the 0µg/ml HCQ control. Data are from three independent 
experiments. *p<0.0001 relative to the control. 
 
 
HCQ has no effect on aPL-induced trophoblast secretion of pro-inflammatory cytokines 
or chemokines 
Having established the HCQ dose, we first sought to determine the effect of HCQ on 
aPL-induced trophoblast inflammation (9, 20, 49). Treatment of trophoblast cells with 
ID2 or IIC5 induced a significant increase in the secretion of IL-8 when compared to the 
no treatment (NT) control. The presence of HCQ had no significant effect on aPL-
induced trophoblast IL-8 production (Figure 2A). Similarly, treatment of trophoblast cells 
with ID2 induced a significant increase in secretion of IL-1β and this was unaffected by 
the presence of HCQ (Figure 2B). HCQ alone had no effect on basal trophoblast IL-8 or 
IL-1β secretion (Figure 2). 




Figure 2: HCQ has no effect on aPL-induced trophoblast secretion of pro-inflammatory cytokines. HTR8 
cells were incubated with either no treatment (NT) or the anti-β2GPI mAbs, ID2 or IIC5 (20µg/ml), in the 
presence of media or HCQ (1µg/ml) for 72hrs. Supernatants were assayed for (A) IL-8 and (B) IL-1β. Data 
are from nine independent experiments. *p<0.05; **p<0.001 relative to the NT control. 
 
 
HCQ has no effect on aPL-induced modulation of trophoblast angiogenic factor 
production 
We next investigated the effect of HCQ on aPL-induced modulation of trophoblast 
angiogenic factor secretion (9, 46, 49). HCQ alone had no effect on basal trophoblast 
secretion of VEGF (Figure 3A), PlGF (Figure 3B), sEndoglin (Figure 3C), or sFlt-1 
(Figure 3D). Treatment of trophoblast cells with ID2 or IIC5 induced a significant 
increase in the secretion of VEGF (Figure 3A). The presence of HCQ significantly 
lowered the ID2-induced VEGF secretion, but had no effect on IIC5-induced VEGF 
(Figure 3A). Treatment of trophoblast cells with ID2 or IIC5 significantly increased 
trophoblast secretion of PlGF, and this was unaffected by HCQ (Figure 3B). Neither ID2 
nor IIC5 in the presence or absence of HCQ had any effect on trophoblast sFlt-1 secretion 
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(Figure 3C). ID2 significantly increased trophoblast secretion of sEndoglin, and this was 




Figure 3: Effect of HCQ on aPL modulation of trophoblast angiogenic factor production. HTR8 cells were 
incubated with either no treatment (NT) or the anti-β2GPI mAbs ID2 or IIC5 (20µg/ml) in the presence of 
media or HCQ (1µg/ml) for 72hrs. Supernatants were assayed for (A) VEGF, (B) PlGF, (C) sFlt-1, and (D) 




HCQ limits aPL-induced inhibition of trophoblast IL-6 secretion and cell migration 
We previously demonstrated that first trimester trophoblast cell production of IL-6 plays 
a role in driving the cell’s spontaneous migration through activation of STAT3, and that 
treatment of first trimester trophoblast cells with aPL decreases constitutive IL-6 
secretion and cell migration (24). Treatment of trophoblast cells with ID2 or IIC5 reduced 
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IL-6 secretion, although not to the level of significance. However, IL-6 secretion in the 
ID2 or IIC5 treatment groups was significantly increased in the presence of HCQ when 
compared to ID2 or IIC5 treatment in the absence of HCQ (Figure 4A). HCQ had no 
significant effect on basal trophoblast IL-6 secretion, although there was an increase 
noted. Treatment of trophoblast cells with ID2 or IIC5 significantly reduced trophoblast 
migration by 65.9±32.0% and 65.6±18.2%, respectively, when compared to the NT 
control. The presence of HCQ had no effect on basal trophoblast migration. However, 
HCQ significantly reversed ID2 and IIC5-inhibition of trophoblast migration, although 




Figure 4: Effect of HCQ on aPL-induced inhibition of trophoblast IL-6 secretion and migration. HTR8 
cells were incubated with either NT or the anti-β2GPI mAbs, ID2 or IIC5 (20µg/ml) in the presence of 
media or HCQ (1µg/ml). (A) After 72hrs supernatants were assayed for IL-6. Data are from five 
independent experiments. *p<0.05 relative to the NT control unless otherwise indicated. (B) After 48hrs, 
cell migration was measured. Data are from four independent experiments. *p<0.05; **p<0.001 relative to 
the NT control unless otherwise indicated. 
 
 
aPL increase secretion of TIMPs and this is partially reversed by HCQ  
Trophoblast migration and invasion have been shown to be partially governed by the 
balance between trophoblast production of the matrix metalloproteinases (MMPs), 
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MMP2 and MMP9, and the tissue inhibitors of matrix metalloproteinases (TIMPs), 
TIMP1 and TIMP2 (80). While treatment of trophoblast cells with aPL had no effect on 
the expression levels of MMP2 or MMP9 (data not shown), treatment with ID2 or IIC5 
significantly increased secretion of TIMP1 and TIMP2 when compared to the NT and 
IgG controls (Figure 5A). Furthermore, treatment of trophoblast cells with recombinant 
(r) TIMP2 significantly reduced trophoblast migration when compared to the NT control 
(Figure 5B). rTIMP2 in combination with rTIMP1 significantly reduced trophoblast 
migration when compared to both the NT control and rTIMP1 alone (Figure 5B). As 
shown in Figure 6, treatment of trophoblast cells with either ID2 or IIC5 significantly 
increased the secretion of (A) TIMP1 and (B) TIMP2, when compared NT control. The 
presence of HCQ significantly inhibited ID2-induced secretion of TIMP1 (Figure 6A). 




Figure 5: aPL upregulate TIMP1 and TIMP2 secretion, which reduces trophoblast migration. (A) HTR8 
cells were incubated with no treatment (NT), the anti-β2GPI mAb ID2 or IIC5 (20µg/ml), or an IgG control 
(20µg/ml) for 72hrs, after which supernatants were assayed for TIMP1 and TIMP2. Data are from four 
independent experiments; **p<0.001 relative to the NT control. (B) HTR8 cells were incubated with either 
NT, recombinant TIMP1 (rTIMP1) at 1ng/ml, recombinant TIMP2 (rTIMP2) at 1ng/ml, or rTIMP1 and 
rTIMP2 at 1ng/ml for 48hrs after which cell migration was measured. Data are from five independent 
experiments. *p<0.05; **p<0.001 relative to NT control unless otherwise indicated. 
 




Figure 6: Effect of HCQ on aPL-induced trophoblast TIMP1 and TIMP2 secretion. HTR8 cells were 
incubated with either no treatment (NT) or the anti-β2GPI mAb ID2 or IIC5 (20µg/ml), in the presence of 
media or HCQ (1µg/ml) for 72hrs. Supernatants were assayed for (A) TIMP1 (n=9) and (B) TIMP2 (n=6). 






We hypothesized that HCQ would prevent the aPL-triggered release of pro-inflammatory 
cytokines, modulation of angiogenic factors, and inhibition of cell migration. We 
specifically hypothesized that HCQ would protect cell migration by preventing aPL-
induced inhibition of pro-migratory factor IL-6 and pro-migratory MMPs, as well as 
preventing aPL-induced upregulation of anti-migratory TIMPs. Our data show that HCQ 
did not prevent the TLR4-mediated pro-inflammatory cytokine response triggered by 
aPL. HCQ was also unable to prevent the aPL-induced modulation of pro- and anti-
angiogenic factor secretion. However, HCQ was able to prevent the aPL-induced 
inhibition of IL-6 production and cell migration. The presence of aPL had no effect on 
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the expression of MMPs, but increased the expression of both TIMP1 and TIMP2. HCQ 
inhibited the aPL-induced secretion of TIMP1, but not TIMP2. 
 
Women with APS continue to face substantial risk for complications during pregnancy, 
even when treated with the standard of care, heparin and/or aspirin. Furthermore, several 
studies have disputed the effects of heparin on aPL-induced abnormal trophoblast cell 
function and have called its efficacy into question (5-10, 81). Thus, further research into 
the potential management of APS-related pregnancy complications is critical. While the 
drug hydroxychloroquine has been used to treat APS and related autoimmune disorders, 
such as lupus, for decades, little is known about its effects on pregnancy outcome in 
patients with aPL (55, 56). Therefore, using an in vitro system, we sought to determine 
the ability of HCQ to alter aPL-mediated modulation of first trimester trophoblast 
function, specifically, cell migration and the secretion of inflammatory cytokines and 
angiogenic factors. In this study, we report that HCQ was able to partially limit aPL-
induced inhibition of trophoblast migration, possibly through the modulation of IL-6 
production.  
 
APS increases the risk of many serious adverse pregnancy outcomes, including recurrent 
pregnancy loss and late gestational complications of preeclampsia, HELLP syndrome, 
premature delivery, and intrauterine growth restriction.  Historically, APS was thought to 
cause pregnancy complications through prothrombotic events within the placenta (16). 
However, during the last decade, obstetric APS has been recognized as a distinct clinical 
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entity from vascular APS, given that patients with APS can display vascular thrombosis 
but no obstetric complications, or vice-versa (13).  
 
Recent clinical and experimental studies suggest that the primary causes for adverse 
pregnancy events are inflammatory processes, namely cytokine production, complement 
deposition, and immune cell activation (18, 20, 21). Studies also indicate that placental 
dysfunction and insufficient placentation play a major role in APS-complicated 
pregnancies (17, 23, 24). This insufficient placentation is related in part to impaired 
migration of trophoblast cells and trophoblast invasion, as well as limited uterine spiral 
artery transformation (17, 23, 24). Because aPL are found in maternal circulation as early 
as the first trimester, and early impairment of placentation is likely a factor in the 
pathology of the obstetric complications of APS, we chose to conduct our investigation 
with an in vitro model using human first trimester trophoblast cells (13). 
 
Recent studies have shown that the immunomodulatory properties of HCQ may be 
explained by an inhibition of TLR signaling, possibly through interference with 
downstream mitogen-activated protein kinase (MAPK) activation and by dampening the 
expression of TLRs and their associated signaling molecules (56, 58, 59, 82). HCQ has 
been suggested to inhibit the functioning of endosome-bound TLRs that degrade nucleic 
acids and are implicated in autoimmune diseases such as APS and lupus (59). Additional 
recent evidence suggests that the fusion and differentiation of trophoblast cells are 
blocked by aPL via a TLR4 pathway, and that HCQ is able to reverse this effect (40). 
Based on this, we postulated that HCQ might prevent the TLR4-dependent trophoblast 
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inflammatory cytokine response induced by aPL (20). Moreover, recent studies have 
demonstrated that HCQ is able to reduce the binding of aPL-β2GPI complexes to 
phospholipid bilayers and protect the anticoagulant protein annexin A5 from disruption 
by aPL in term trophoblast cells (72-74). In our initial experiments, we found that high 
doses of HCQ (10µg/ml and 100µg/ml) negatively affected cell viability. Therefore, a 
dose of 1µg/ml was selected for use in further experiments, which correlated with 
concentrations previously used (72-74).  
 
We found that HCQ alone had no significant effect on basal trophoblast secretion of 
inflammatory cytokines or angiogenic factors. Moreover, HCQ had no effect on aPL-
induced IL-8 and IL-1β production, suggesting that the ability of HCQ to inhibit TLR4 
signaling may not be applicable to the trophoblast (82). Alternatively, it could be a 
reflection of the short period of exposure of the trophoblast to HCQ. While an in vitro 
exposure to HCQ can inhibit activation of the endosomal TLRs (58), the ability of HCQ 
to down-modulate the TLR4 signaling pathway has only been shown in vivo after a long 
term exposure of 6 months (82). Our data also suggest that HCQ does not prevent anti-
β2GPI mAbs binding to first trimester trophoblast cells. This is in contrast to what has 
been reported for the effects of HCQ on aPL-β2GPI complexes binding to lipid bilayers 
and for aPL binding to term trophoblast, even though for these studies as well as our own, 
aPL and HCQ were delivered to the cells at the same time (72-74). While HCQ had no 
effect on aPL-induced PlGF or sEndoglin secretion, we did observe a slight, but 
significant, reduction in VEGF secretion induced by one of the anti-β2GPI mAbs, ID2. 
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This is in keeping with a study showing that that chloroquine reduces epidermal VEGF 
expression (83). 
 
While HCQ did not have an overt effect on the angiogenic factor profile, nor did it 
prevent aPL-induced trophoblast inflammation, we did observe an effect on the aPL-
mediated reduction in IL-6 secretion and cell migration. Conflicting reports of the effects 
of HCQ on cell migration exist, but its effects on migration in the trophoblast have not 
been extensively studied (84, 85). It has previously been reported that treatment of 
trophoblast cells with aPL reduced basal IL-6 secretion, STAT3 phosphorylation, and 
trophoblast migration (24). Moreover, trophoblast migration has been shown to be 
inhibited by blocking the IL-6-to-IL-6 receptor interaction, suggesting this to be the 
mechanism by which aPL limit cell migration (24). In this current study, HCQ was able 
to reverse the effect of aPL on IL-6 production. However, the aPL-induced reduction in 
cell migration was only partially reversed by the presence of HCQ. This finding suggests 
that while HCQ might have a beneficial effect on aPL-induced inhibition of trophoblast 
migration, another factor in addition to IL-6 may be involved in its regulation, and this 
factor is not altered by HCQ.  
 
Trophoblast migration and invasion can be regulated by the balance between the cell’s 
production of the matrix metalloproteinases, MMP2 and MMP9, and the tissue inhibitors 
of matrix metalloproteinases, TIMP1 and TIMP2 (80). Therefore, we sought to determine 
whether aPL disrupted this balance of MMPs and TIMPs in the trophoblast, and whether 
the presence of HCQ provided any protection. Unlike previous reports that have shown 
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aPL to reduce MMP2 and MMP9 expression in trophoblast cells, we found MMP2 and 
MMP9 expression to be unchanged after exposure to either of the anti-β2GPI mAbs (43, 
47, 48).  
 
Instead, our data show for the first time that aPL upregulate both TIMP1 and TIMP2 
secretion, and that the presence of recombinant TIMP2 either alone, or in combination 
with TIMP1, can limit trophoblast migration, similarly to treatment with aPL or 
disruption of IL-6 signaling (24). However, the presence of HCQ was not able to entirely 
prevent ID2-induced TIMP1 secretion and had no protective effect on aPL-induced 
TIMP2 secretion. Our findings are supported by previous data that chloroquine promotes 
endothelial cell migration (84), and are inconsistent with previous reports that 
chloroquine increases TIMP1 in serum levels of patients with lupus (85). Our studies 
indicate that the beneficial effects of HCQ on IL-6 and TIMP1 secretion, but its inability 
to affect TIMP2 secretion, may explain why HCQ was able to improve but not wholly 
reverse the inhibition of trophoblast migration by aPL. These data are mirrored by a 
recent study examining the effects of an anti-inflammatory product of aspirin, aspirin-
triggered lipoxin (ATL), on HTR8 cell function (50). This study found that ATL was able 
to reverse both the aPL-induced downregulation of IL-6 and the inhibition of cell 
migration, reinforcing the importance of IL-6 levels in migration of trophoblast cells, 
previously shown to be related to the STAT3 pathway (24). This study also found that 
aPL induced an upregulation of TIMP2, supporting our data. The upregulation of TIMP2 
was not reversed by ATL. This evidence, in combination with our study, could suggest 
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that there are multiple mechanisms by which aPL inhibit trophoblast migration, and that 
drugs such as HCQ and ATL target some but not all of these pathways. 
 
In summary, our research demonstrates that HCQ was able to partially but significantly 
reverse the aPL-induced inhibition of trophoblast migration. Our research showed that 
HCQ was able to reverse the aPL-induced down-regulation of promigratory cytokine IL-
6, and was able to partially reverse the aPL-induced upregulation of TIMP1. However, 
HCQ was found to have no effect on aPL-induced upregulation of pro-inflammatory 
cytokines or aPL-induced modulation of angiogenic factors. Our study did not reveal any 
overt negative effects of HCQ on basal trophoblast function.  Together, our data indicate 
that HCQ may be useful as a therapeutic agent to target pregnancy complications in 
women with APS. Moreover, the potential benefit of HCQ on trophoblast migration, but 
not on the inflammatory or angiogenic profile, suggests that a combination therapy that 
includes HCQ may offer greater protection to women with APS during pregnancy.  
 
It is important to note that these in vitro studies may not perform as a comprehensive 
model of the in vivo condition of APS during pregnancy. Our results show that HCQ has 
no negative effect on basal trophoblast function, and there is a broad fund of research 
demonstrating the safety of HCQ in pregnancy, as it is often used to treat APS and lupus 
as an anti-inflammatory and immunomodulatory drug. Therefore, it may be useful to 
examine whether HCQ can produce any benefits during pregnancy in the APS population 
as a clinical trial. In cases with APS patients at high risk for obstetrical complications, it 
could also be argued that HCQ may be a safe and viable option for treatment. However, 
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further experimentation is necessary to determine the optimal combination of drug 
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